- Details
- In this episode of Kidney Cancer Today, Monty Pal and Jamie Landman team up with Laura Bukavina and Lee Ponsky to discuss consults for benign renal cysts undergoing unnecessary active surveillance. Among other topics, their conversation especially touches on present flaws in the healthcare system, including the appropriate evaluation of renal cysts and healthcare disparities in accessibility to ac...
|
- Details
- Daniel Watson and Alan Burns present their collaborative approach in favor of percutaneous renal mass cryoablation for renal masses. To date, Dr. Watson and Burns have done 207 of these procedures. The mean age of the patient is approximately 69 years and the mean size of the lesions is about 2.3 centimeters. Dr. Watson suggests a 85% cure rate with this procedure. Biographies: Daniel L. Watson, M...
|
- Details
- James Borin speaks about the revolution and the evolution of percutaneous renal surgery. The evolution of the technique is now using ultrasound guidance and smaller scopes, mini-percs with endoscopic guidance. Dr. Borin answers the following questions during his presentation: who can have a supine PCNL? What is it?, and When should it be done ambulatory? He also describes what he calls a hybrid pr...
|
- Details
- Ashley Baker presents on percutaneous renal biopsy in the ambulatory surgery center. Dr. Baker presents in favor of urologists being involved and of the safety of the procedure being performed in the ambulatory surgery center. Biographies: Ashley Baker, MD, Urology Specialist, Shreveport, Louisiana, USA. Moderator: Evan R. Goldfischer, MD, MBA Related Content: Biopsy of the Small Renal Mass - Stil...
|
- Details
- Neeraj Agarwal, MD discusses the recent update to the CARMENA trial which was presented at ASCO 2019. The Phase 3 non-inferiority CARMENA trial comparing sunitinib versus nephrectomy followed by sunitinib established that patients could avoid nephrectomy without compromising survival. This benefit was seen in both the intermediate and poor risk subgroups. In the updated data presented at ASCO 2019...
|
- Details
- Jens Bedke enthusiastically discusses the transformation in first-line treatment of RCC from monotherapy, which has been the standard of care on the treatment of RCC to now combination therapies. The first-line therapy with a combination of an immune checkpoint inhibitor and a tyrosine kinase inhibitor (TKI) improved outcomes in patients with clear-cell metastatic renal cell carcinoma (mRCC), as c...
|
- Details
- Colleagues, Jaime Landman and Zhamshid Okhunov discuss office-based, ultrasound-guided renal mass biopsy. Jaime details the simplicity of this technique, the best candidate for this procedure, and the value in doing a renal biopsy with this technique. Biographies: Jaime Landman, MD Professor and Chairman, UCI Department of Urology, UC Irvine Medical Center Zhamshid Okhunov, MD, Urology Fellow, Dep...
|
- Details
- Dena Battle, President KCCure joins Jaime Landman and Monty Pal for a discussion on development and establishing resources to assist in the fight against kidney cancer. KCCure, is a research organization that funds high-impact, high-risk kidney cancer research through a peer-review processthrough an expert team of kidney cancer specialists, patients, caregivers, and kidney cancer advocates. The gr...
|
- Details
- (Length of Discussion: 9 min) Alicia Morgans and Toni Choueiri provide a review of the historical background evolving from the era of targeted therapy to the current landscape in kidney cancer incorporating the surprising results from the CARMENA trial. Biographies: Toni K. Choueiri, MD, Jerome and Nancy Kohlberg Professor of Medicine, Harvard Medical School, Attending Physician, Solid Tumor Oncol...
|
